✦ LIBER ✦

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

✍ Scribed by T.-Christian H. Mix; Robert M. Brenner; Mark E. Cooper; Dick de Zeeuw; Peter Ivanovich; Andrew S. Levey; Janet B. McGill; John J.V. McMurray; Patrick S. Parfrey; Hans-Henrik Parving; Brian J.G. Pereira; Giuseppe Remuzzi; Ajay K. Singh; Scott D. Solomon; Catherine Stehman-Breen; Robert D. Toto; Marc A. Pfeffer

Book ID: 116189918
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 181 KB
Volume: 149
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2004.09.047

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline Characteristics in the Trial to

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

✍ Marc A. Pfeffer; Emmanuel A. Burdmann; Chao-Yin Chen; Mark E. Cooper; Dick de Ze 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 287 KB

Predictors of fatal and nonfatal cardiov

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

✍ John J.V. McMurray; Hajime Uno; Petr Jarolim; Akshay S. Desai; Dick de Zeeuw; Ka 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 463 KB

Reducing Cardiovascular Events in High-R

Reducing Cardiovascular Events in High-Risk Patients: The Challenge of Managing Hypertension in Patients With Diabetic Renal Disease

✍ Robert D. Toto 📂 Article 📅 2007 🏛 Le Jacq Communications, Inc. 🌐 English ⚖ 165 KB

139 Evaluating the cardiac rehabilitatio

139 Evaluating the cardiac rehabilitation paradigm in the management of cardiovascular risk in patients with chronic kidney disease

✍ T.L. Parsons; M. DeYoung; D. Hopkins-Rosseel; W. Hopman; S. Lahaye 📂 Article 📅 2011 🏛 Pulsus Group Inc 🌐 English ⚖ 127 KB

CARDIOVASCULAR EVENT RATES IN STABLE COR

CARDIOVASCULAR EVENT RATES IN STABLE CORONARY PATIENTS WITH CHRONIC KIDNEY DISEASE, INCREASED BY THE PRESENCE OF OBESITY, ARE REDUCED BY INTENSIVE LIPID LOWERING WITH ATORVASTATIN

✍ Prakash C. Deedwania; James Shepherd; Daniel J. Wilson 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Cardiovascular outcomes and their relati

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial

✍ I. Holme; R. Fayyad; O. Faergeman; J. J. P. Kastelein; A. G. Olsson; M. J. Tikka 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB